Neuren's Phase 2 trial for NNZ-2591 shows significant improvements in Pitt Hopkins syndrome, with no serious adverse events.

Neuren's Phase 2 trial shows significant improvements in Pitt Hopkins syndrome, with clinician and caregiver global efficacy measures demonstrating clinically meaningful improvements in communication, social interaction, cognition, and motor abilities. NNZ-2591 proved safe and well tolerated, with no serious or severe adverse events. The positive trial result strengthens confidence in the drug's potential relevance.